<DOC>
	<DOCNO>NCT00253955</DOCNO>
	<brief_summary>Primary Objective : - The primary objective study demonstrate non-inferiority clinical efficacy test cure ( TOC ) visit plan 5-7 day treatment completion levofloxacin 750 mg daily ( od ) comparison piperacillin/tazobactam 4 g/500 mg every 8 hour treat adult patient suffer mild moderate hospital-acquired pneumonia . Secondary Objectives : The secondary objective study : - To assess bacteriological efficacy test cure ( TOC ) visit - To assess clinical bacteriological efficacy end study ( EOS ) visit , 28 32 day treatment end - To assess tolerability drug</brief_summary>
	<brief_title>Study Demonstrate Clinical Efficacy Levofloxacin Treatment Pneumonia</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Tazobactam</mesh_term>
	<mesh_term>Piperacillin</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<mesh_term>Piperacillin , tazobactam drug combination</mesh_term>
	<mesh_term>Penicillanic Acid</mesh_term>
	<criteria>Subjects meet follow criterion consider enrollment study : General ward ICU hospitalize subject . Subject diagnosis hospitalacquired pneumonia presume bacterial origin base upon : Infection develop least 72 hour follow hospital admission At least three four follow sign : Fever , define body temperature ( oral tympanic temperature ≥ 38°C rectal temperature ≥ 38.5°C ) Purulent tracheal sputum production/secretion change sputum character Total peripheral white blood cell ( WBC ) count &gt; 12 G/L &lt; 4.5 G/L 15 % immature neutrophil ( band ) , regardless total peripheral WBC count Increased plasma serum C reactive protein ( CRP ) level show level least twice upper boundary hospital normal range Chest Xray finding ( anterior posterior [ AP ] posterior anterior [ PA ] , possible lateral view ) agreement clinical diagnosis bacterial pneumonia , i.e . appearance new , progressive pulmonary infiltrate ( ) attributable infectious etiology . Subjects require specimen collect microbiological documentation within 24 hour prior enrolment . Specimens include least one invasive noninvasive low respiratory tract specimen Gram stain , culture susceptibility testing , least 2 venous blood sample culture susceptibility test . Subjects present follow include study : Related hospitalacquired pneumonia ( HAP ) : Suspected viral fungal pneumonia , HAP strongly suspect caused MRSA ( methicillinresistant Staphylococcus aureus ) organisms responsible atypical pneumonia , Chlamydia pneumoniae , Legionella pneumophila Mycoplasma pneumoniae Patients severe HAP , define presence least one following : In previously nonventilated patient : need mechanical ventilation consequently HAP In previously ventilate patient : oxygenation rate define partial pressure oxygen arterial blood ( PaO2 ) /fraction inspire oxygen ( FiO2 ) &lt; 200 Radiographic finding compatible severe HAP , i.e . show either : Rapid progression ( e.g . increase size opacity ≥ 50 % within 48 hour current evaluation ) OR multilobar pneumonia ( &gt; 2 lobe ) involvement lung OR cavitation lung infiltrate Evidence severe sepsis hypotension and/or endorgan dysfunction , i.e . : Shock commonly evidence : systolic blood pressure &lt; 90 mmHg diastolic blood pressure &lt; 60 mmHg In absence previous vasopressor use , vasopressor use ( except fluid replacement ) 4 hour In presence vasopressor use , increase vasopressor use ( except fluid replacement ) 4 hour OR mark reduction urine output ( unless another explanation available ) , i.e . 1 hour : &lt; 20 mL 4 hour : &lt; 80 mL OR acute renal failure require dialysis OR profound alteration mental status , i.e . mark lethargy/stupor/coma Related medical history/concomitant condition : Patients concomitant pulmonary disease , condition complication could confound interpretation evaluation drug efficacy safety , include severe bronchiectases , cystic fibrosis , active pulmonary tuberculosis acute pulmonary embolism , empyema , lung abscess extra pulmonary extension LRTI ( low respiratory tract infection ) , meningitis , septic arthritis , endocarditis , know bronchial obstruction due tumor foreign body history postobstructive pneumonia ( exclude patient COPD [ chronic obstructive pulmonary disease ] ) , primary lung cancer another malignancy metastatic lung , and/or require chemotherapeutic treatment ( reason ) Patients know suspected bacterial infection disease investigation require concomitant use systemic antimicrobial agent study drug allocate Patients receive previous systemic antibiotic longer 24 hour within 72 hour prior enrolment episode HAP Body weight &gt; 95 kg Patients impaired renal function , show creatinine clearance &lt; 20 mL/min Hepatic cirrhosis ChildPugh score &gt; = B Immunocompromised patient , present either : Known HIV infection CD4 + Tlymphocyte count &lt; 0.2 G/L ( i.e . &lt; 200 cells/mm3 ) Neutropenia neutrophil count &lt; 1.0 G/I ( i.e . &lt; 1000/mm3 ) Patients maintenance ( ≥ 3 month ) corticosteroid therapy ( &gt; 20 mg/day equivalent prednisolone ) Related study drug : Patients microbiologically document infection pathogen know prior inclusion resistant least one study medication Patients know suspected hypersensitivity , know suspect serious adverse reaction levofloxacin and/or piperacillin/tazobactam and/or quinolones , betalactamase inhibitor , penicillin and/or cephalosporins Patients epilepsy history epilepsy predisposition seizure ( e.g . patient preexist central nervous system lesion ) Patients know suspected history tendon disorder unless potential relationship fluoroquinolone administration exclude . Patients latent actual know defect glucose6phosphate dehydrogenase activity General : Women breastfeed , fail use adequate contraception ; example , systemic hormone ( birth control pill , implant ) , intrauterine device barrier method ( diaphragm intravaginal spermicide , cervical cap , male female condom ) , pregnant , demonstrated urine serum pregnancy test carry exposure study medication start study procedure could pose risk foetus Patients recent ( within three month prior study entry ) history drug alcohol abuse Patients receive investigational drug within one month prior study entry . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2008</verification_date>
</DOC>